As a result of direct or indirect antagonism of IL-6 via the JAK-STAT pathway, it has been shown to improve the prognosis of hospitalized COVID-19 patients with hypoxia and systemic inflammation, IL-6 may be a biomarker closely related to treatment (56). Here, IL6 is linked to COVID-19.